Evidence map›Paper›PMID 29672542›Full record

ArticlePloS one2018

Attrition when providing antiretroviral treatment at CD4 counts >500cells/μL at three government clinics included in the HPTN 071 (PopART) trial in South Africa.

Peter Bock, Geoffrey Fatti, Nathan Ford, Karen Jennings, James Kruger, Colette Gunst, Françoise Louis, Nelis Grobbelaar, Kwame Shanaube, Sian Floyd and 6 more

Registry-linked trialOpen access · goldAbstract read
In one paragraph

Article in PloS one, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01900977 (Population Effects of Antiretroviral Therapy to Reduce HIV Transmission), which is not on this map. Cited by 16 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed, 1 pooled it
2.0field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01900977 nacompletednot on this map

Population Effects of Antiretroviral Therapy to Reduce HIV Transmission (PopART): A Cluster-randomized Trial of the Impact of a Combination Prevention Package on Population-level HIV Incidence in Zambia and South Africa

TypeinterventionalSponsorHIV Prevention Trials NetworkRan2014 to 2018Enrolled48,540ConditionsHIVArmsUniversal Testing with immediate ART, Universal Testing with ART eligibility according to National Guidelines, Standard of Care
3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 1 synthesis or guideline pooled it, 26 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Review
  6. CD4+ T-Cell Count at Antiretroviral Therapy Initiation in the "Treat-All" Era in Rural South Africa: An Interrupted Time Series Analysis.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2022
    Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 9 institutions in 3 countries.

Peter BockDesmond Tutu TB Centre, Department of Paediatrics and Child Health, Faculty of Medicine and Health Sciences, Stellenbosch University, Tygerberg Campus, Western Cape, South Africa.ORCID 0000-0003-3211-6078
Geoffrey FattiKheth' Impilo, Foreshore, Cape Town, South Africa.
Nathan FordCentre for Infectious Disease Epidemiology and Research, University of Cape Town, Cape Town, South Africa.
Karen JenningsCity of Cape Town Health Services, Foreshore, Cape Town, South Africa.
James KrugerWestern Cape Department of Health, HIV Treatment & PMTCT programme, Cape Town, South Africa.
Colette GunstWestern Cape Department of Health Cape Winelands District Brewelskloof Hospital, Worcester, South Africa.
Françoise LouisKheth' Impilo, Foreshore, Cape Town, South Africa.
Nelis GrobbelaarANOVA Healthcare, Paarl, South Africa.
Kwame ShanaubeZambart, University of Zambia, Ridgeway Campus, Lusaka, Zambia.
Sian FloydDepartment of Infectious Disease Epidemiology, London School of Hygiene and Tropical Medicine, London, United Kingdom.
Ashraf GrimwoodKheth' Impilo, Foreshore, Cape Town, South Africa.
Richard HayesDepartment of Infectious Disease Epidemiology, London School of Hygiene and Tropical Medicine, London, United Kingdom.
Helen AylesZambart, University of Zambia, Ridgeway Campus, Lusaka, Zambia.
Sarah FidlerDepartment of Medicine, Imperial College London, St Mary's Campus, London, United Kingdom.
Nulda BeyersDesmond Tutu TB Centre, Department of Paediatrics and Child Health, Faculty of Medicine and Health Sciences, Stellenbosch University, Tygerberg Campus, Western Cape, South Africa.
HPTN 071 (PopART) trial team
Kheth’Impilo · ZADesmond Tutu HIV Foundation · ZALondon School of Hygiene & Tropical Medicine · GBUniversity of Zambia · ZMWestern Cape Department of Health · ZAAnova Health Institute · ZACity of Cape Town · ZAImperial College London · GBUniversity of Cape Town · ZA

Funding

LOC: HIV Prevention Trials NetworkUM1AI068619 · NIAID · FAMILY HEALTH INTERNATIONAL · PI Sinead Delany-Moretlwe, RAPHAEL J LANDOVITZ · 2011 to 2026
$779.5M
SDMC: HPTN 084 Pregnancy SupplementUM1AI068617 · NIAID · FRED HUTCHINSON CANCER RESEARCH CENTER · PI Elizabeth Renata Brown, Deborah J Donnell · 2011 to 2026
$204.9M
LC: HIV Prevention Trials Network - Laboratory Support for the SARS-CoV-2 Seroprevalence Study (CoVPN 5002)UM1AI068613 · NIAID · JOHNS HOPKINS UNIVERSITY · PI SUSAN H ESHLEMAN, Mark A Marzinke · 2011 to 2026
$100.2M
Medical Research Council MR/K012126/1NIAID NIH HHS UM1 AI068613NIAID NIH HHS UM1 AI068617NIAID NIH HHS UM1 AI068619NIH HHS UM1-AI068613NIH HHS UM1-AI068617NIH HHS UM1-AI068619
6 · The paper itself

Abstract

introductionWHO recommends antiretroviral treatment (ART) for all HIV-positive individuals. This study evaluated the association between baseline CD4 count and attrition in a cohort of HIV positive adults initiating ART at three department of health (DOH) clinics routinely providing ART at baseline CD4 counts >500cells/μL for the HPTN 071 (PopART) trial.

methodsAll clients attending the DOH clinics were managed according to standard care guidelines with the exception that those starting ART outside of pertinent local guidelines signed research informed consent. DOH data on all HIV-positive adult clients recorded as having initiated ART between January 2014 and November 2015 at the three study clinics was analysed. Attrition, included clients lost to follow up or died, and was defined as 'being three or more months late for an antiretroviral pharmacy pick-up appointment'. All clients were followed until attrition, transfer out or end May 2016.

resultsA total of 2423 clients with a median baseline CD4 count of 328 cells/μL (IQR 195-468) were included of whom 631 (26.0%) experienced attrition and 140 (5.8%) were TFO. Attrition was highest during the first six months of ART (IR 38.3/100 PY; 95% CI 34.8-42.1). Higher attrition was found amongst those with baseline CD4 counts > 500 cells/μL compared to those with baseline CD4 counts of 0-500 cells/μL (aHR 1.26, 95%CI 1.05 to 1.52) This finding was confirmed on subset analyses when restricted to individuals non-pregnant at baseline and when restricted to individuals with follow up of > 12months.

conclusionsAttrition in this study was high, particularly during the first six months of treatment. Attrition was highest amongst clients starting ART at baseline CD4 counts > 500 cells/μL. Strategies to improve retention amongst ART clients, particularly those starting ART at baseline CD4 counts >500cells/μL, need strengthening. Improved monitoring of clients moving in and out of ART care and between clinics will assist in better understanding attrition and ART coverage in high burden countries.

Indexed as

CD4 Lymphocyte CountAdolescentAdultAnti-HIV AgentsAntiretroviral Therapy, Highly ActiveClinical Trials as TopicFemaleGovernment ProgramsHIV InfectionsHumansKaplan-Meier EstimateMaleMiddle AgedProportional Hazards ModelsSouth AfricaTreatment OutcomeAnti-HIV Agents

Identifiers

PMID29672542
PMCPMC5909512
OpenAlexW2801707625

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.